COVID-19 in hematopoietic stem-cell transplant recipients: A systematic review and meta-analysis of clinical characteristics and outcomes

Imagem de Miniatura
Arquivos
art_RANDI_COVID19_in_hematopoietic_stemcell_transplant_recipients_A_systematic_2023.PDF (800.47 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
SILVA, Vinicius Ponzio da
Citação
REVIEWS IN MEDICAL VIROLOGY, v.33, n.6, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Patients who undergo hematopoietic stem-cell transplantation (HSCT) are more susceptible to developing severe forms of COVID-19 with an increased risk of mortality. The aim of this study was to analyze, by performing a systematic review and meta-analysis, all studies that evaluated COVID-19 in HSCT adult recipients and present clinical characteristics and outcomes. Studies were eligible for inclusion if they: (I) described the clinical characteristics of COVID-19 in adult (aged 18 years old or above) HSCT recipients; (II) described outcomes of COVID-19 in this population, mainly lethality; (III) were full-text articles. We searched MedLine, Embase, SCOPUS, LILACS and Web of Science for full-text studies that evaluated COVID-19 in adult HSCT patients until 26 Apr 2023. Two independent reviewers screened the articles and extracted the data. The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Studies Reporting Prevalence Data was used to assess quality of the included studies. Meta-analysis was performed and the pooled prevalence of severe/critical disease and of death with a 95% CI was calculated with the random-effects model. Sixteen studies were included; seven (43.7%) were multicenter. Most of the studies were from Europe (37.5%). All of them had a low risk of bias using the JBI Checklist. A total of 1186 patients were included. Allogeneic HSCT patients were the majority in most studies, with a total of 861 patients (72.5%). The symptomatic rate was 79.4%. The pooled prevalence of severe/critical COVID-19 was 24.0% (95% CI 0.13-0.36; I2 = 94%; n = 334/990). The pooled prevalence of death for the entire population was 17% (95% CI 0.13-0.22; I2 = 76%; n = 221/1117), 17% (95% CI 0.12-0.23; I2 = 67%; n = 152/822) for allogeneic-HSCT and 14% (95% CI 0.08-0.22; I4 = 65%; n = 48/293) for autologous-HSCT. In conclusion, frequently the infection of SARS-CoV-2 in HSCT was symptomatic and lethality is higher than in general population. Thus, it is essential to focus on the implementation of measures to mitigate the risk of SARS-CoV-2 infection in this population, as well as to carefully assess HSCT recipients who develop COVID-19.
Palavras-chave
COVID-19, hematopoietic stem cell transplantation, SARS-CoV-2
URI
https://observatorio.fm.usp.br/handle/OPI/57839
Referências
  1. Alsohime F, 2020, J INFECT PUBLIC HEAL, V13, P1791, DOI 10.1016/j.jiph.2020.10.008
  2. Altuntas F, 2021, BONE MARROW TRANSPL, V56, P952, DOI 10.1038/s41409-020-01084-x
  3. Busca A, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1125030
  4. Busca A, 2022, BLOOD ADV, V6, P1427, DOI 10.1182/bloodadvances.2021005616
  5. Camargo JF, 2021, TRANSPL INFECT DIS, DOI 10.1111/tid.13625
  6. Chaekal OK, 2022, TRANSPL CELL THER, V28, DOI 10.1016/j.jtct.2022.06.012
  7. Coll E, 2021, AM J TRANSPLANT, V21, P1825, DOI 10.1111/ajt.16369
  8. Daudt LE, 2022, BONE MARROW TRANSPL, V57, P453, DOI 10.1038/s41409-021-01561-x
  9. Doesum JAV, 2023, BLOOD ADV, V7, P2645, DOI 10.1182/bloodadvances.2022009578
  10. Ge CH, 2022, EXP HEMATOL ONCOL, V11, DOI 10.1186/s40164-022-00299-6
  11. Gholami M, 2023, INT J PUBLIC HEALTH, V68, DOI 10.3389/ijph.2023.1605421
  12. Guarino M, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-08947-x
  13. Hausinger RI, 2023, VACCINES-BASEL, V11, DOI 10.3390/vaccines11040863
  14. Jondreville L, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01387-0
  15. Karatas A, 2021, TURK J MED SCI, V51, P1647, DOI 10.3906/sag-2103-72
  16. Kimura M, 2022, TRANSPL CELL THER, V28, DOI 10.1016/j.jtct.2022.07.024
  17. Komanduri KV, 2013, IMMUNOL RES, V57, P140, DOI 10.1007/s12026-013-8461-4
  18. Marta GN, 2021, JCO GLOB ONCOL, V7, P1084, DOI 10.1200/GO.21.00087
  19. Mittal A, 2023, TRANSPL CELL THER, V29, DOI 10.1016/j.jtct.2023.08.008
  20. Moher D, 2010, INT J SURG, V8, P336, DOI [10.1016/j.ijsu.2010.02.007, 10.1016/j.ijsu.2010.07.299, 10.1371/journal.pmed.1000097, 10.1136/bmj.b2700, 10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]
  21. Munn Z, 2015, INT J EVID-BASED HEA, V13, P147, DOI 10.1097/XEB.0000000000000054
  22. Mushtaq MU, 2021, TRANSPL CELL THER, V27, DOI 10.1016/j.jtct.2021.07.005
  23. National Institute of Health, 2023, COR DIS 2019 COVID 1
  24. National Institute of Health, 2023, PREV SARS COV 2 INF
  25. Ogonek J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00507
  26. Passamonti F, 2020, LANCET HAEMATOL, V7, pE737, DOI 10.1016/S2352-3026(20)30251-9
  27. Piechotta V, 2022, BLOOD CANCER J, V12, DOI 10.1038/s41408-022-00684-8
  28. Pinana JL, 2023, BONE MARROW TRANSPL, V58, P567, DOI 10.1038/s41409-023-01946-0
  29. Piñana JL, 2021, J INFECT DIS, V223, P1564, DOI 10.1093/infdis/jiaa553
  30. Sahin U, 2016, J INFECT CHEMOTHER, V22, P505, DOI 10.1016/j.jiac.2016.05.006
  31. Schaffrath J, 2022, TRANSPL CELL THER, V28, DOI 10.1016/j.jtct.2022.03.010
  32. Shah GL, 2020, J CLIN INVEST, V130, P6656, DOI 10.1172/JCI141777
  33. Silfverberg T, 2022, UPSALA J MED SCI, V127, DOI 10.48101/ujms.v127.8611
  34. Sim SA, 2018, BIOL BLOOD MARROW TR, V24, P1490, DOI 10.1016/j.bbmt.2018.03.004
  35. Siniaev AA., 2022, KMAX
  36. Soheili M, 2023, ANN CLIN MICROB ANTI, V22, DOI 10.1186/s12941-023-00594-y
  37. Tan JY, 2023, TRANSPL INFECT DIS, V25, DOI 10.1111/tid.14024
  38. Udomkarnjananun S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-99713-y
  39. van den Brink MRM, 2015, HEMATOL-AM SOC HEMAT, P215, DOI 10.1182/asheducation-2015.1.215
  40. Varma A, 2020, LEUKEMIA, V34, P2809, DOI 10.1038/s41375-020-01019-x
  41. Watanabe M, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10111830
  42. Wood WA, 2020, BLOOD ADV, V4, P5966, DOI 10.1182/bloodadvances.2020003170
  43. World Health Organization WH, US
  44. Yang WJ, 2020, RADIOLOGY, V295, pE3, DOI 10.1148/radiol.2020200702

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - LIM/49
Carregar mais